Indeed, we observed in erlotinib-sensitized IGROV-1 cells a significant increase of resistance to FasLigand in a dose-dependent manner (Figure 2a), whereas tumor cell sensitivity to TRAIL remained unaffected by sensitization (Figure 2b). Here, TNFSF10 is linked to neoplasm.